相似文献
1
Polymorphically acetylated aminoglutethimide in humans.
Br J Cancer. 1982 Sep;46(3):340-5. doi: 10.1038/bjc.1982.209.
2
The effect of acetylator phenotype on the disposition of aminoglutethimide.
Br J Clin Pharmacol. 1984 Oct;18(4):495-505. doi: 10.1111/j.1365-2125.1984.tb02497.x.
3
N-acetylation phenotyping with sulphadimidine in a Turkish population.
Eur J Clin Pharmacol. 1990;38(1):53-6. doi: 10.1007/BF00314803.
4
Effect of concomitant isoniazid administration on determination of acetylator phenotype by sulphadimidine.
Eur J Clin Pharmacol. 1986;30(4):463-6. doi: 10.1007/BF00607961.
5
Evaluation of the sulphadimidine acetylator phenotyping test in patients with reduced renal function.
Acta Med Scand. 1981;209(6):505-7. doi: 10.1111/j.0954-6820.1981.tb11636.x.
6
Possible optimization of sulphadimidine dosage for acetylator phenotyping.
Jpn J Pharmacol. 1991 Aug;56(4):531-4. doi: 10.1254/jjp.56.531.
7
Sulphamethoxazole acetylation in fast and slow acetylators.
Int J Clin Pharmacol Ther Toxicol. 1990 Apr;28(4):164-6.
8
Comparison between serum and urinary sulphadimidine acetylation as predictors of isoniazid acetylator status in patients with pulmonary tuberculosis.
Indian J Chest Dis Allied Sci. 1996 Jan-Mar;38(1):5-11.
9
Acetylator phenotype and congenital malformations.
Eur J Clin Pharmacol. 1989;36(2):151-3. doi: 10.1007/BF00609187.
10
The effect of glucose on acetylation status.
Br J Clin Pharmacol. 1986 Oct;22(4):401-8. doi: 10.1111/j.1365-2125.1986.tb02909.x.
引用本文的文献
1
Clinical pharmacokinetics of aromatase inhibitors and inactivators.
Clin Pharmacokinet. 2003;42(7):619-31. doi: 10.2165/00003088-200342070-00002.
2
The effect of acetylator phenotype on the disposition of aminoglutethimide.
Br J Clin Pharmacol. 1984 Oct;18(4):495-505. doi: 10.1111/j.1365-2125.1984.tb02497.x.
3
Single-dose and steady-state pharmacokinetics of aminoglutethimide.
Clin Pharmacokinet. 1985 Jul-Aug;10(4):353-64. doi: 10.2165/00003088-198510040-00005.
4
High-performance liquid chromatographic assay for simultaneous estimation of aminoglutethimide and acetylaminoglutethimide in biological fluids.
Cancer Chemother Pharmacol. 1985;15(2):176-8. doi: 10.1007/BF00257533.
5
Could aminoglutethimide replace adrenalectomy?
Breast Cancer Res Treat. 1985;6(3):201-11. doi: 10.1007/BF01806770.
6
Metabolism of aminoglutethimide in humans: quantification and clinical relevance of induced metabolism.
Br J Cancer. 1985 Feb;51(2):259-62. doi: 10.1038/bjc.1985.37.
7
Clinical pharmacology of aminoglutethimide in patients with metastatic breast cancer.
Cancer Chemother Pharmacol. 1987;20(4):337-41. doi: 10.1007/BF00262588.
8
Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer.
Drugs. 1988 Jun;35(6):685-710. doi: 10.2165/00003495-198835060-00005.
9
Genetically determined variability in acetylation and oxidation. Therapeutic implications.
Drugs. 1985 Apr;29(4):342-75. doi: 10.2165/00003495-198529040-00003.
10
Aminoglutethimide in advanced breast cancer: plasma levels and clinical results after low and high doses.
Cancer Chemother Pharmacol. 1991;27(6):451-5. doi: 10.1007/BF00685159.
本文引用的文献
1
HUMAN ACETYLATION POLYMORPHISM.
J Lab Clin Med. 1964 Mar;63:394-403.
2
Transformylation of carcinogenic aromatic by kynerenine formamidase: a detoxication mechanism.
Biochem Pharmacol. 1968 Jun;17(6):1110-3. doi: 10.1016/0006-2952(68)90370-5.
3
An improved and simplified method of detecting the acetylator phenotype.
J Med Genet. 1969 Dec;6(4):405-7. doi: 10.1136/jmg.6.4.405.
4
Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine.
J Lab Clin Med. 1970 Jul;76(1):114-25.
5
Identification of the mononitro derivative of dapsone as a product from an oxidation in vitro.
Biochem Pharmacol. 1973 Jun 1;22(11):1383-5. doi: 10.1016/0006-2952(73)90312-2.
6
N-hydroxylation of 4,4'-diaminodiphenylsulphone in liver microsomes and in vivo.
Xenobiotica. 1971 Jul-Oct;1(4):501-2. doi: 10.3109/00498257109041517.
7
The partial fate of aminoglutethimide in man.
J Pharm Pharmacol. 1972 Dec;24:Suppl:150P.
8
Synthesis of an active hydroxylated glutethimide metabolite and some related analogs with sedative-hypnotic and anticonvulsant properties.
J Med Chem. 1975 Jul;18(7):736-41. doi: 10.1021/jm00241a019.
9
Artifacts formed in the metabolic study of pethidine.
Acta Pharm Suec. 1978;15(1):71-5.
10
Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome.
N Engl J Med. 1978 May 25;298(21):1157-9. doi: 10.1056/NEJM197805252982101.
Zotero 插件